select semaglutide trial Beyond obesity: Novo's re-defines cardiovascular risk management Phase 3 Trial of Semaglutide

The no-untoward-effect level in humans has been estimated to be 52.5 mg of quinine a day, which is about a two and a half cups (590 ml) of tonic water

On 21 May 2026, Lilly announced positive topline results from TRIUMPH-1 (not yet peer-reviewed), the pivotal Phase 3 obesity trial

This prompted an emergency referral by ambulance to Groote Schuur Hospital, where Nodela was observed overnight as a surgical team was assembled

Obesity and Dietary Added Sugar Interact to Affect Postprandial GLP-1 and Its Relationship to Striatal Responses to Food Cues and Feeding Behavior

Reducing visceral fat can significantly improve overall well-being by addressing both physical and metabolic health